<span item_type="fundamental" item_id="ef508b70ff2877c28bfc0a5a4f0aef5d" counter_id="ST/US/ARMP" env="prod"></span><span item_type="announcement" item_id="548724940547231105" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.45.</p><p></p><h3>Operating Loss</h3><ul><li>Operating loss for the three months ended June 30, 2025, was $6.8 million, compared to $11.9 million for the same period in 2024, representing a decrease of 42.6%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss for the three months ended June 30, 2025, was $16.3 million, compared to a net income of $9.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm"></span></li></ul><h3>Research and Development Expenses</h3><ul><li>Research and development expenses decreased by $2.1 million, from $8.5 million for the three months ended June 30, 2024, to $6.4 million for the same period in 2025, primarily due to decreased clinical trial costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm"></span></li></ul><h3>General and Administrative Expenses</h3><ul><li>General and administrative expenses were $2.6 million for the three months ended June 30, 2025, a decrease from $3.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was $14.8 million for the six months ended June 30, 2025, compared to $20.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li>Armata Pharmaceuticals, Inc. plans to continue the development of its phage-based therapeutics, focusing on advancing its lead candidates, AP-PA02 and AP-SA02, through clinical trials. The company aims to secure additional funding to support these initiatives and potentially resume clinical development of AP-PA02 for non-cystic fibrosis bronchiectasis.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li>The company is exploring potential strategic partnerships to further advance its programs and is considering revising its clinical trial protocols to include additional indications for its phage products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/921114/000155837025011235/armp-20250630x10q.htm"></span></li></ul>

Armata Pharmaceuticals | 10-Q: FY2025 Q2 EPS: USD -0.45